T he continuous exposure of vascular endothelium to circulating lymphocytes, together with its ability to express pleiotropic major histocompatibility complex (MHC) antigens in pathological conditions,1-3 imparts this tissue with the ability to greatly amplify the immune response toward genetically incompatible grafts, or self-antigens, in certain autoimmune diseases. 4 Accumulating evidence also supports the notion that microvascular endothelium can be involved as a primary target of functional rejection in vascularized allografts. Endo-thelial cell (EC) injury has been demonstrated in early stages of rejection, with perivascular mononuclear cell infiltrates and interendothelial cell gaps rapidly progressing to blood vessel lining disruption. 5 The immunohistological demonstration of EC involvement in allogeneic as well as self-directed immune response has prompted a number of in vitro studies focused on the immunogenicity of vascular endothelium. Our group6 and other groups7 have shown that cultured ECs, either constitutively or after exposure to lymphocyte-derived cytokines, express functionally normal MHC determinants, in addition to polymorphic surface antigens largely restricted to this tissue. 8 were recovered and used as effectors in 51Cr release assays. These assays were performed in flat-bottomed microtiter wells with confluent EC monolayers, either autologous or allogeneic to the stimulating EC line, which had been labeled with 2 ,Ci/well 5`Cr for 2 hours at 37°C. Spontaneous and maximum release was determined by incubating labeled targets in culture medium or 0.7% Triton X-100 in glycerol/ water, respectively. Mean corrected percent lysis in triplicate culture was calculated as follows: cytotoxicity (%)=(mean experimental cpm-spontaneous release cpm)/(maximum release cpm-spontaneous release cpm)x100. Spontaneous release was always <20% of maximum release.
In some experiments, monoclonal antibodies (10 ,ug/ml) were added either directly to the 4-hour assay or used to pretreat either the effector or target cells for 30 minutes at 37°C, after which unbound antibody was washed out and the assay was performed. In other experiments, ACs were treated with 500 ,uM chloroquine at the onset of the 7-day stimulation period. In preliminary experiments, 500 ,uM chloroquine gave the most efficient functional inhibition without affecting cell viability (not shown) and was therefore used in subsequent experiments. ACs were suspended at 1 x 106/ml in RPMI medium containing 500 ,uM chloroquine for 30 minutes at 37°C, after which they were flooded with 10% fetal calf serum, washed twice, irradiated (30 Gy) , and added to the responder cells for the 7-day culture. Alternatively, ACs were pulsed overnight with the relevant ECs at a 1:10 (AC: EC) ratio and chloroquine-treated the next day before the initiation of the 7-day culture. In other experiments, the natural killer (NK)-sensitive line K562 was 51Cr-labeled (50 LCi/106 cells) and used as a target in cytotoxicity assays.
Results

Basal Requirements for the Generation ofAnti-EC T-Cell-Mediated Immune Response
Primary sensitization in vitro of highly purified T cells or T-cell subsets with allogeneic microvascular ECs is not sufficient to stimulate a detectable anti-EC cytotoxic response ( Figure 1 body inhibition studies of this clone confirmed the results obtained at the bulk culture level, demonstrating the involvement of the CD3/T-cell receptor complex and the CD4 molecule in both the inductive and effector phases of the anti-EC response by CD4' lymphocytes (Table 2) . Anti-MHC class I and two anti-HLA-DR antibodies recognizing nonoverlapping epitopes of the DR molecule were again unable to inhibit the allogeneic EC-specific cytotoxicity mediated by cells of the CD4' sublineage. When y-interferon-treated, MHC class II-expressing ECs were used as stimulators to generate allospecific CD4+ CTL clones, the recognition pattern of the effector cells was at variance with the results observed using MHC class II negative stimulators. Under these circumstances, the majority of the CTL clones tested appeared to recognize MHC class II determinants, as shown by the absence of killing of Ia negative EC targets and by the inhibition of class IL+ EC target lysis observed using anti-class II monoclonal antibodies (Table 3) . Discussion Donor microvascular endothelium is likely to be involved both as a stimulus and as a target in EIT ratio, effector to target cell ratio. inability to stimulate allogeneic T cells reflects either defective "accessory" cell function (i.e., soluble factor production or antigen processing capabilities) or insufficient expression of MHC class II allodeterminants to be recognized by allospecific T cells. The induction of alloantigen-specific T-cell proliferation and cytotoxicity to allogeneic ECs in the presence of low concentrations of IL-1 or IL-2 ( Figure 1 and Table 1 ) would suggest that surface alloantigens displayed by ECs are normally recognized by precursor T cells, whereas the IL-1 mediated activation pathway involved in the afferent limb of the T-celldependent immune response28 is defective. This conclusion is supported by the experiments performed with CD8' cells ( Figure 1 and Table 1) , which were induced to lyse the sensitizing EC line if as little as 2 units/ml IL-2 were present in the 7-day cultures. This result suggests that CD8+ cells express (Table 3) . Nonetheless, the likelihood of detecting such activity in CD4+ lymphocytes cultured for 1 week with allogeneic ECs seemed low, since HLA-DP, -DQ, and -DR antigens are not detectable on microvascular ECs under these conditions (Figure 4 ). Clonal analysis of the CD4+ cell-mediated anti-EC cytotoxic response demonstrates that, at least in some instances, the same cell can be induced to proliferate in response to the relevant EC alloantigens and to differentiate toward the final effector CTLs ( Table 2 ). The presence in the sensitizing culture of autologous ACs appears to be a condition necessary and sufficient for generating a detectable response by CD4+ cells in our experimental model. The activity of autologous ACs in the culture system is not replaceable by IL-1 or IL-2 ( Figure 1 and Table  1 ), but it is completely abrogated by the treatment of ACs with 500 ,uM chloroquine before alloantigen pulsing ( Figure 5 ). This strongly suggests that intracellular processing of allogeneic EC-derived antigens is required to trigger the recognition of allogeneic EC determinants by CD4+ lymphocytes. Results obtained with an allogeneic EC-specific CD4+ clone ( 
